🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesIs it possible to reverse type 2 or am I dreaming Page 2

Is it possible to reverse type 2 or am I dreaming

steve_okc Mon, May 11, 2026 at 8:28 PM 13 replies 519 viewsPage 2 of 3
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
May 11, 2026 at 10:18 PM#6
sarah.morrison said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

3 23steve_okc, dave_SLC, FDA_TrackerJim
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
May 11, 2026 at 11:01 PM#7
steve_okc said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 36% to 22%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

2 22Dr.ObesityLA, NurseKim_ATL
Reply Quote Save Share Report
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
May 11, 2026 at 11:44 PM#8
PeptideChemSF said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)120989282
Insulin (fasting)261285
HOMA-IR4.53.12.01.4
Uric Acid7.87.05.95.1

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

1 21PharmacoVig_BOS
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
May 12, 2026 at 12:27 AM#9

Following on from Dr.GastroMayo — and this may be the naive question:

Was that from a primary source or from a summary of one?

50 20jennifer_SEA, tyler_CSCS, VanRx_Mike and 47 others
Reply Quote Save Share Report
steve_okc
Member
489
2,123
Jul 2024
Oklahoma City, OK
May 12, 2026 at 3:54 AM#10
Dr.NephBHM_UK said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

My labs after 12 months on glycaemic control: A1C 5.5%, fasting glucose 90 mg/dL, fasting insulin 9 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.5% and fasting glucose was 115 mg/dL. The improvement has been dramatic and consistent.

Last edited: May 12, 2026 at 7:54 AM
48 23KetoKyle, CanadaChris, ZaraB_AL and 45 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register